Invesco’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$258K Buy
1,045,232
+44,940
+4% +$17.9K ﹤0.01% 3400
2025
Q4
$420K Buy
1,000,292
+191,561
+24% +$102K ﹤0.01% 3266
2025
Q3
$545K Buy
808,731
+128,279
+19% +$69.2K ﹤0.01% 3204
2025
Q2
$368K Buy
680,452
+196,558
+41% +$117K ﹤0.01% 3291
2025
Q1
$317K Buy
483,894
+219,253
+83% +$232K ﹤0.01% 3341
2024
Q4
$270K Sell
264,641
-33,533
-11% -$61.3K ﹤0.01% 3446
2024
Q3
$258K Sell
298,174
-16,347
-5% -$12K ﹤0.01% 3459
2024
Q2
$113K Buy
314,521
+26,502
+9% +$14.3K ﹤0.01% 3736
2024
Q1
$193K Buy
288,019
+125,745
+77% +$91.2K ﹤0.01% 3658
2023
Q4
$88.2K Sell
162,274
-22,605
-12% -$10.4K ﹤0.01% 3701
2023
Q3
$111K Buy
184,879
+5,597
+3% +$5.99K ﹤0.01% 3704
2023
Q2
$233K Buy
179,282
+11,801
+7% +$16.1K ﹤0.01% 3572
2023
Q1
$295K Buy
167,481
+26,407
+19% +$75.4K ﹤0.01% 3506
2022
Q4
$443K Buy
141,074
+6,384
+5% +$24.8K ﹤0.01% 3334
2022
Q3
$660K Sell
134,690
-3,779
-3% -$19.4K ﹤0.01% 3102
2022
Q2
$573K Buy
138,469
+10,282
+8% +$44.5K ﹤0.01% 3263
2022
Q1
$744K Buy
128,187
+41,891
+49% +$249K ﹤0.01% 3210
2021
Q4
$646K Sell
86,296
-7,013
-8% -$60.9K ﹤0.01% 3277
2021
Q3
$840K Sell
93,309
-708,564
-88% -$7M ﹤0.01% 3192
2021
Q2
$9.6M Buy
801,873
+44,410
+6% +$503K ﹤0.01% 2080
2021
Q1
$9.49M Buy
757,463
+51,023
+7% +$688K ﹤0.01% 1983
2020
Q4
$11M Buy
706,440
+85,784
+14% +$1M ﹤0.01% 1752
2020
Q3
$5.87M Buy
620,656
+562,474
+967% +$6.08M ﹤0.01% 1934
2020
Q2
$521K Sell
58,182
-5,983
-9% -$55.5K ﹤0.01% 3111
2020
Q1
$409K Buy
64,165
+39,019
+155% +$290K ﹤0.01% 3148
2019
Q4
$210K Sell
25,146
-1,648
-6% -$15.2K ﹤0.01% 3521
2019
Q3
$242K Sell
26,794
-1,044
-4% -$11.7K ﹤0.01% 3498
2019
Q2
$300K Sell
27,838
-868,229
-97% -$9.23M ﹤0.01% 3503
2019
Q1
$8.55M Buy
896,067
+271,590
+43% +$2.77M ﹤0.01% 1669
2018
Q4
$7.17M Buy
624,477
+135,124
+28% +$1.68M ﹤0.01% 1732
2018
Q3
$8.29M Sell
489,353
-82,159
-14% -$1.25M ﹤0.01% 1834
2018
Q2
$8.12M Sell
571,512
-429,251
-43% -$7.13M ﹤0.01% 1801
2018
Q1
$19M Sell
1,000,763
-375,265
-27% -$8.02M 0.01% 1194
2017
Q4
$22.6M Sell
1,376,028
-3,177
-0.2% -$47.3K 0.01% 1154
2017
Q3
$20.7M Buy
1,379,205
+1,324,698
+2,430% +$14.6M 0.01% 1182
2017
Q2
$480K Sell
54,507
-456
-0.8% -$2.93K ﹤0.01% 3337
2017
Q1
$286K Buy
54,963
+25,261
+85% +$101K ﹤0.01% 3518
2016
Q4
$91K Buy
29,702
+829
+3% +$3.02K ﹤0.01% 3610
2016
Q3
$134K Buy
28,873
+5,360
+23% +$27.3K ﹤0.01% 3577
2016
Q2
$136K Sell
23,513
-87
-0.4% -$554 ﹤0.01% 3602
2016
Q1
$143K Buy
+23,600
New +$142K ﹤0.01% 3618
2015
Q3
Sell
-1,356,752
Closed -$15M 3964
2015
Q2
$15M Buy
1,356,752
+311,858
+30% +$4.02M 0.01% 1340
2015
Q1
$16.4M Buy
1,044,894
+914,584
+702% +$14.2M 0.01% 1300
2014
Q4
$1.98M Buy
130,310
+21,420
+20% +$260K ﹤0.01% 2518
2014
Q3
$1.18M Sell
108,890
-879,944
-89% -$11.5M ﹤0.01% 2873
2014
Q2
$15.1M Buy
988,834
+741
+0.1% +$10.7K 0.01% 1356
2014
Q1
$17.9M Buy
988,093
+820,727
+490% +$15.8M 0.01% 1240
2013
Q4
$2.33M Sell
167,366
-528,272
-76% -$6.08M ﹤0.01% 2577
2013
Q3
$7.3M Buy
695,638
+694,750
+78,238% +$6.9M ﹤0.01% 1659
2013
Q2
$7K Buy
+888
New +$7.75K ﹤0.01% 4217

Other funds holding SGMO

Invesco's SGMO Position: Q1 2026 in Review

Invesco increased its SANGAMO THERAPEUTICS INC (SGMO) stake by 4.5% in Q1 2026, buying an estimated $17.9K and bringing the position to 1,045,232 shares worth $258K. The position accounts for ﹤0.01% of the portfolio, ranked #3400.

Invesco first reported a position in SGMO in Q2 2013 and has held it in 50 quarters since. The position peaked at $22.6M in Q4 2017. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • Invesco held 1,045,232 shares of SANGAMO THERAPEUTICS INC worth $258K as of Q1 2026.
  • Invesco bought 44,940 SANGAMO THERAPEUTICS INC shares in Q1 2026, an estimated $17.9K.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #3400 holding.
  • Invesco first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and has held it in 50 quarters since.
  • Invesco's SANGAMO THERAPEUTICS INC position peaked at $22.6M in Q4 2017.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.